NCT03760744: Imaging Biomarkers of Lymphatic Dysfunction

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Not Applicable
Drug Category: Other

Key Eligibility Criteria:

Gender: Female
Age: 30 Years to 90 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with lymphedema in both arms or pre-existing lymphedema/swelling in the upper body prior to cancer treatments

Comments are closed.

Up ↑